AZD1222 US Phase III Trial
The AstraZeneca’s AZD1222 US Phase III Trial demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease…
The AstraZeneca’s AZD1222 US Phase III Trial demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease…
On March 15, the Centers for Medicare & Medicaid Services (CMS) is increasing the Medicare payment amount for administering the COVID-19 vaccine.“This new and higher…
The Centers for Disease Control and Prevention (CDC), on March 17, announced a plan to invest $2.25 billion over two years to address Coronavirus Disease…
On March 17, the U.S. Food and Drug Administration (FDA) granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), the first SARS-CoV-2 diagnostic test…
CVS Health, on March 16, announced the availability of COVID-19 antibody testing in all MinuteClinic locations in Massachusetts, there are nearly 60 MinuteClinic locations in…
Recently the National Community Pharmacists Association (NCPA) released a new survey, according to which, Americans shows a strong preference to receive the COVID-19 vaccines from…
The US Food and Drug Administration (FDA) recently writes an article about a growing interest in a drug called ivermectin to treat humans with COVID-19….
Recently CVS Health announced that they have nearly doubled the number of states where select CVS Pharmacy locations are offering COVID-19 vaccines to eligible populations…
On March 10, Eli Lilly and Company announced new data from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 3 study, demonstrating bamlanivimab (LY-CoV555) 700 mg and…
On March 8, the Centers for Disease Control and Prevention (CDC) issued its first set of recommendations on activities that people who are fully vaccinated…